Medical University of Vienna - Recruiting 18 years to 40 years. - The Effect of Ticagrelor and Apixaban With or Without Acetylsalicylic Acid on Markers of Coagulation Activation at the Site of Thrombus Formation in Vivo in Healthy Male Subjects and in an ex Vivo Perfusion Chamber Model at High and Low Shear Rate.
OrbusNeich - Recruiting 20 years or older. - Japan-USA Harmonized Assessment by Randomized, Multi-Center Study of OrbusNEich's Combo StEnt (Japan-USA HARMONEE): Assessment of a Novel DES Platform For Percutaneous Coronary Revascularization in Patients With Ischemic Coronary Disease and NSTEMI Acute Coronary Syndrome.
OrbusNeich R stentT; Everolimus Eluting Stent (EES)
Catholic University of the Sacred Heart - Recruiting 50 years to 80 years. - Effects of TIcaGREloR on Circulating Microparticles and Micro-RNAs in Patients With Non ST Elevation Acute Coronary Syndromes.
Hospital do Coracao - Recruiting 18 years or older. - A Randomized, Multicenter Clinical Trial to Assess the Effect of Atorvastatin in Patients With Acute Coronary Syndrome and Intended Percutaneous Coronary Intervention.
AstraZeneca - Recruiting N/A or older. - A Retrospective Swedish Cohort Study on Health Outcomes, Life Expectancy, Resource Use and Costs in Patients With a History of Myocardial Infarction and Additional Risk Factors for Atherothrombosis.
Sanofi - Recruiting 40 years or older. - A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Effect of Alirocumab (SAR236553/REGN727) on the Occurrence of Cardiovascular Events in Patients Who Have Recently Experienced an Acute Coronary Syndrome.
Bayer - Recruiting 18 years or older. - A Prospective, Randomized, Verum Controlled, Open Label, Parallel Group Multi-center Phase III Clinical Trial to Demonstrate the Superiority of 500 or 250 mg Aspirinr i.v. (BAY 81-8781) Treatment Versus 300 mg Aspirinr N Tablets p.o. (BAY e4465A) in Patients With Acute Coronary Syndrome, Measured by Time Dependent Thromboxane Inhibition.
Deutsches Herzzentrum Muenchen - Recruiting 18 years or older. - A Randomized, Parallel Group, Double-Blind Study of Ticagrelor Compared With Aspirin for Prevention of Vascular Events in Patients Undergoing Coronary Artery Bypass Graft Operation TiCAB- Ticagrelor in CABG.
Medical University of Graz - Recruiting 18 years to 90 years. - Bleeding in Patients Undergoing Urgent CABG During Dual Antiplatelet Therapy Including the New P2Y12 Receptor Inhibitors Prasugrel and Ticagrelor.
Inha University Hospital - Recruiting 18 years to 80 years. - Comparison of Clopidogrel and Ticagrelor on Microvascular Dysfunction in Acute Coronary Syndrome Patients: The Index of MIcrocirculatory Resistance After PCI in ACS Patients Study (TIMER Study).
Deutsches Herzzentrum Muenchen - Recruiting 18 years or older. - Prospective, Randomized Trial of Ticagrelor Versus Prasugrel in Patients With Acute Coronary Syndrome - Intracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary Treatment (ISAR-REACT) 5.
AstraZeneca - Recruiting 18 years or older. - A Multicenter, Single Arm, Open Label, Phase IV Study to Evaluate Safety and to Describe the Incidence of Major Cardiovascular Events of Ticagrelor in Chinese Patients With Acute Coronary Syndrome(ACS).
Les Laboratoires des Mdicaments Striles - Recruiting 20 years or older. - Comparison of Anti-Xa Activity in the Treatment With Enoxaparin in ACS Admitted to the Emergency. Randomized Clinical Trial ENOXA r Versus LOVENOX r.
Deutsches Herzzentrum Muenchen - Recruiting 18 years or older. - ISAR-DESIRE 4: Randomized Trial Of Scoring Balloon in Patients With Restenosis in 'Limus'-Eluting Coronary Stents Undergoing Angioplasty With Paclitaxel-Coated Balloon.
University of Bari - Recruiting 18 years to 80 years. - Effects of the Administration Of Antithrombin on the Coagulation Status and on the Inflammatory Response in Patients With Low Plasmatic Levels of Antithrombin After Cardiac Surgery.
Clearstream Technologies Ltd. - Recruiting 18 years or older. - OCT Evaluation of Stent Struts Re-endothelization in Patients With Acute Coronary Syndromes: a Comparison of the IntrepideT Stent vs. TaxusT.
Intrepide Trapidil eluting stent; Taxus drug eluting stent